Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain

Journal of Nuclear Medicine

Volumn 57, Issue 5, 2016, Pages 777-784

  Nabulsi, Nabeel B ^a   Mercier, Jol ^b   Holden, Daniel ^a   Carr, Stephane ^b   Najafzadeh, Soheila ^a   Vandergeten, Marie Christine ^b   Lin, Shu Fei ^a   Deo, Anand ^b   Price, Nathalie ^b   Wood, Martyn ^b   Lara Jaime, Teresa ^a   Montel, Florian ^b   Laruelle, Marc ^c   Carson, Richard E ^a   Hannestad, Jonas ^b   Huang, Yiyun ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UCB PHARMA   (Belgium)

^c Intracellular Therapeutics   (United States)

Author keywords

11C UCB J; Biomarker; Epilepsy; Levetiracetam; Nonhuman primate; PET; Rhesus monkey; SV2A; Synaptic vesicle glycoprotein

Indexed keywords

1 ((3 (11C METHYL 11C)PYRIDIN 4 YL)METHYL) 4 ((3,4,5 TRIFLUOROPHENYL)PYRROLIDIN 2 ONE); GLYCOPROTEIN; SYNAPTIC VESICLE GLYCOPROTEIN 2A; TRACER; UNCLASSIFIED DRUG; 1-((3-(METHYLPYRIDIN-4-YL)METHYL)-4-(3,4,5-TRIFLUOROPHENYL)PYRROLIDIN-2-ONE; 2 PYRROLIDONE DERIVATIVE; MEMBRANE PROTEIN; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE;

1 TISSUE COMPARTMENT MODEL; ADULT; AMYGDALA; ANIMAL EXPERIMENT; APPARENT PERMEABILITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN STEM; CAUDATE NUCLEUS; CELL MEMBRANE PERMEABILITY; CEREBELLUM; CINGULATE GYRUS; COMPARTMENT MODEL; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; FRONTAL CORTEX; GLOBUS PALLIDUS; GRAY MATTER; IMAGE ANALYSIS; IN VITRO STUDY; INHIBITION CONSTANT; INSULA; MALE; METABOLIC CLEARANCE; NONHUMAN; NUCLEUS ACCUMBENS; OCCIPITAL CORTEX; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RADIOCHEMISTRY; RAT; RECEPTOR BINDING; RHESUS MONKEY; SUBSTANTIA NIGRA; SYNTHESIS; TEMPORAL CORTEX; THALAMUS; VOLUME OF DISTRIBUTION; ANIMAL; BRAIN; CHEMISTRY; DIAGNOSTIC IMAGING; HUMAN; METABOLISM; PERMEABILITY; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; CHEMISTRY TECHNIQUES, SYNTHETIC; FEMALE; HUMANS; MACACA MULATTA; MALE; MEMBRANE GLYCOPROTEINS; PERMEABILITY; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; PYRROLIDINES; PYRROLIDINONES; RADIOCHEMISTRY; RATS; TISSUE DISTRIBUTION;

EID: 84966891639     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.168179     Document Type: Article

References (31)

1. Bajjalieh SM, Peterson K, Shinghal R, Scheller R. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science. 1992;257:1271-1273.
2. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14:5223-5235.
3. Vogl C, Tanifuji S, Danis B, et al. Synaptic vesicle glycoprotein 2A modulates vesicular release and calcium channel function at peripheral sympathetic synapses. Eur J Neurosci. 2015;41:398-409.
4. Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA. 1999;96:15268-15273.
5. Gillard M. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006;536:102-108.
6. Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds. Jasper's Basic Mechanisms of the Epilepsies. 4th ed. Bethesda, MD: National Center for Biotechnology Information (US); 2012:83.
7. Kaufman AC, Salazar SV, Haas LT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol. 2015;77:953-971.
8. Robinson JL, Molina-Porcel L, Corrada MM, et al. Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. Brain. 2014;137:2578-2587.
9. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A. Integrative genomics identifies APOE e4 effectors in Alzheimer's disease. Nature. 2013;500: 45-50.
10. Cai H, Mangner TJ, Muzik O, Wang MW, Chugani DC, Chugani HT. Radiosynthesis of 11C-levetiracetam: A potential marker for PET imaging of SV2A expression. ACS Med Chem Lett. 2014;5:1152-1155.
11. Mercier J, Archen L, Bollu V, et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: Opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem. 2014;9:693-698.
12. Lubberink M, Estrada S, Thibblin A, et al. Pre-clinical evaluation and kinetic modelling of 11C-UCB-A as a PET tracer for synaptic vesicle protein 2A. Abstract presented at: The 10th International Symposium on Functional NeuroReceptor Mapping of the Living Brain; May 21-24, 2014, Amsterdam, The Netherlands.
13. Estrada S, Thibblin A, Johansen P, et al. Synthesis, biodistribution and radiation dosimetry of 11C-UCB-A, a novel PET tracer for synaptic vesicle protein 2A. Abstract presented at: The 10th International Symposium on Functional NeuroReceptor Mapping of the Living Brain; May 21-24, 2014; Amsterdam, The Netherlands.
14. Warnock GI, Aerts J, Bahri MA, et al. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. J Nucl Med. 2014;55:1336-1341.
15. Zheng M-Q, Holden D, Nabulsi N, et al. Synthesis and evaluation of 18F-UCB-H, a novel PET imaging tracer for the synaptic vesicle protein 2A [abstract]. J Nucl Med. 2014;55(suppl 1):1792.
16. Bretin F, Bahri MA, Bernard C, et al. Biodistribution and radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H: First-in-human study. Mol Imaging Biol. 2015;17:557-564.
17. Fuks B, Gillard M, Michel P, et al. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol. 2003;478:11-19.
18. Gillard M, Fuks B, Michel P, Vertongen P, Massingham R, Chatelain P. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol. 2003;478:1-9.
19. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861-9866.
20. Nabulsi N, Hannestad J, Holden D, et al. [11C]UCB-J: A novel PET tracer for imaging the synaptic vesicle glycoprotein 2A (SV2A) [abstract]. J Nucl Med. 2014;55(suppl 1):355.
21. Sandiego CM, Weinzimmer D, Carson RE. Optimization of PET-MR registrations for nonhuman primates using mutual information measures: A multi-transform method (MTM). Neuroimage. 2013;64:571-581.
22. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000; 27:627-630.
23. del Rosario RB, Jung Y-W, Baidoo KE, Lever SZ, Wieland DM. Synthesis and in vivo evaluation of a 99m99Tc-DADT-Benzovesamicol: A potential marker for cholinergic neurons. Nucl Med Biol. 1994;21:197-203.
24. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22:1271-1281.
25. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: The Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46-50.
26. Soloducho J, Olech K, Swist A, Zajac D, Cabaj J. Recent advances of modern protocol for C-C bonds: The Suzuki Cross-Coupling. ACES. 2013;3:19-32.
27. Kuivila HG, Reuwer JF Jr, Mangravite JA. Electrophilic displacement reactions: XV-kinetics and mechanism of the base-catalyzed protodeboronation of areneboronic acids. Can J Chem. 1963;41:3081-3090.
28. Kuivila HG. Electrophilic displacement reactions. XVI. Metal ion catalysis in the protodeboronation of areneboronic acids. J Am Chem Soc. 1964;86:2666-2670.
29. Lambeng N, Gillard M, Vertongen P, Fuks B, Chatelain P. Characterization of [3H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord. Eur J Pharmacol. 2005;520:70-76.
30. Van Der Aart J, Hallett WA, Rabiner EA, Passchier J, Comley RA. Radiation dose estimates for carbon-11-labelled PET tracers. Nucl Med Biol. 2012;39:305-314.
31. Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN. A graphical method to compare the in vivo binding potential of PET radioligands in the absence of a reference region: Application to [11C]PBR28 and [18F]PBR111 for TSPO imaging. J Cereb Blood Flow Metab. 2014;34:1162-1168.